Develops peptide drug candidates for patients with endocrine and metabolic disorders, including chronic hypoparathyroidism, obesity and post-bariatric hypoglycemia.
10-K for FY2025, filed Mar 12, 2026We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide…View ↗
Canvuparatide: Our lead product candidate, canvuparatide (MBX 2109), is a parathyroid hormone ("PTH") peptide prodrug that is designed as a…View ↗
Obesity portfolio: Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent "PEP™ glucagon-like…View ↗
Imapextide: Our program, imapextide (MBX 1416), is designed to be a long-acting GLP-1 receptor antagonist as a potential therapy for…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 12, 2026
10-Q for Q3 FY2026, filed Nov 9, 2026
−$62.4MView ↗
8-K, filed Aug 6, 2026
Executive Appointments to Support Next Phase of Growth: Steve Hoerter, current Executive Chairman of the MBX Board, was appointed Chairman…View ↗
Competes with Ascendis Pharma, AstraZeneca, Extend Biosciences, Septerna, BridgeBio/Calcilytix, Eli Lilly and, Novo Nordisk, Amgen, Roche, Viking Therapeutics, Zealand Pharma, Boehringer Ingelheim, Amylyx Pharmaceuticals, Vogenx, and Recordati
10-K for FY2025, filed Mar 12, 2026Ascendis Pharma has Yorvipath approved in the United States, EU, Australia, and Japan for the treatment of HP in adults.View ↗
Loading...